Vertex Pharmaceuticals Gestion

Gestion contrôle des critères 2/4

Le PDG Vertex Pharmaceuticals est Reshma Kewalramani, nommé en Apr2020, a un mandat de 4.58 ans. La rémunération annuelle totale est $ 20.59M, composée du salaire de 7.3% et des bonus 92.7%, y compris les actions et options de la société. détient directement 0.029% des actions de la société, d'une valeur de $ 34.17M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 5.1 ans et 4.8 ans.

Informations clés

Reshma Kewalramani

Directeur général

US$20.6m

Rémunération totale

Pourcentage du salaire du PDG	7.3%
Durée du mandat du directeur général	4.6yrs
Propriété du PDG	0.03%
Durée moyenne d'occupation des postes de direction	5.1yrs
Durée moyenne du mandat des membres du conseil d'administration	4.8yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Reshma Kewalramani a-t-elle évolué par rapport aux bénéfices de Vertex Pharmaceuticals?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-US$480m
Jun 30 2024	n/a	n/a	-US$490m
Mar 31 2024	n/a	n/a	US$4b
Dec 31 2023	US$21m	US$2m	US$4b
Sep 30 2023	n/a	n/a	US$3b
Jun 30 2023	n/a	n/a	US$3b
Mar 31 2023	n/a	n/a	US$3b
Dec 31 2022	US$16m	US$1m	US$3b
Sep 30 2022	n/a	n/a	US$3b
Jun 30 2022	n/a	n/a	US$3b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	US$15m	US$1m	US$2b
Sep 30 2021	n/a	n/a	US$2b
Jun 30 2021	n/a	n/a	US$2b
Mar 31 2021	n/a	n/a	US$3b
Dec 31 2020	US$9m	US$1m	US$3b
Sep 30 2020	n/a	n/a	US$3b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$7m	US$702k	US$1b

Rémunération vs marché: La rémunération totale de Reshma ($USD 20.59M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché UK ($USD 5.66M ).

Rémunération et revenus: La rémunération de Reshma a augmenté alors que l'entreprise n'est pas rentable.

PDG

Reshma Kewalramani (51 yo)

4.6yrs

Titularisation

US$20,594,441

Compensation

Dr. Reshma Kewalramani, M.D., FASN, is Director at Year Up Inc. since September 2023. She had been an Independent Director of Ginkgo Bioworks Holdings, Inc. (formerly known as Ginkgo Bioworks, Inc.) since...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Jeffrey Leiden	Executive Chairman	15.3yrs	US$6.60m	0.0040% $ 4.7m
Reshma Kewalramani	CEO, President & Director	4.6yrs	US$20.59m	0.029% $ 34.2m
Charles Wagner	Executive VP & CFO	5.6yrs	US$7.37m	0.017% $ 19.9m
Stuart Arbuckle	Executive VP & COO	3.3yrs	US$9.00m	0.019% $ 22.5m
David Altshuler	Executive VP & Chief Scientific Officer	9.8yrs	US$6.54m	0.010% $ 11.6m
Kristen Ambrose	Senior VP & Chief Accounting Officer	3.5yrs	pas de données	0.0029% $ 3.4m
Mike Tirozzi	SVP and Chief Information & Data Officer	5.8yrs	pas de données	pas de données
Susie Lisa	Senior Vice President of Investor Relations	2.2yrs	pas de données	pas de données
Jonathan Biller	Executive VP & Chief Legal Officer	2.2yrs	pas de données	0.0065% $ 7.5m
Nina Devlin	Senior VP & Chief Communications Officer	5.8yrs	pas de données	pas de données
Stephanie Franklin	Senior VP & Chief Human Resources Officer	7.3yrs	pas de données	pas de données
Amit Sachdev	Executive VP & Chief Patient and External Affairs Officer	17.3yrs	US$6.20m	0.023% $ 26.2m

5.1yrs

Durée moyenne de l'emploi

57yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de 0QZU est chevronnée et expérimentée (5.1 années d'ancienneté moyenne).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Jeffrey Leiden	Executive Chairman	15.3yrs	US$6.60m	0.0040% $ 4.7m
Reshma Kewalramani	CEO, President & Director	4.8yrs	US$20.59m	0.029% $ 34.2m
Bruce Sachs	Lead Independent Director	26.8yrs	US$600.04k	0.016% $ 18.0m
Alan Garber	Independent Director	7.4yrs	US$537.63k	0.0023% $ 2.7m
Lloyd Carney	Independent Director	5.8yrs	US$559.79k	0.0021% $ 2.4m
Sangeeta Bhatia	Independent Director	9.4yrs	US$550.31k	0.0013% $ 1.5m
Michel Lagarde	Independent Director	1.1yrs	US$449.08k	pas de données
Diana McKenzie	Independent Director	4.4yrs	US$553.11k	0.00064% $ 743.3k
Suketu Upadhyay	Independent Director	2.5yrs	US$544.66k	0.00060% $ 696.8k
Nancy Thornberry	Independent Director	less than a year	US$407.65k	pas de données
Jennifer Schneider	Independent Director	less than a year	pas de données	pas de données

4.8yrs

Durée moyenne de l'emploi

59yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 0QZU sont considérés comme expérimentés (ancienneté moyenne 4.8 ans).

Vertex Pharmaceuticals Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Vertex Pharmaceuticals Incorporated Appoints Jennifer Schneider as Independent Director

Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 15, 2024

Vertex Pharmaceuticals Incorporated Appoints Nancy Thornberry to Its Board of Directors as an Independent Director

Vertex Pharmaceuticals Incorporated Appoints Michel Lagarde to Its Board of Directors

Vertex Pharmaceuticals Incorporated Appoints E. Morrey Atkinson, Ph.D., as Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations

Insufficient new directors

Recent updates

Third quarter 2024 earnings released: EPS: US$4.05 (vs US$4.01 in 3Q 2023)

Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024

Vertex Pharmaceuticals Incorporated to Report Q3, 2024 Results on Nov 04, 2024

Second quarter 2024 earnings released: US$13.92 loss per share (vs US$3.55 profit in 2Q 2023)

Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024

Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-To-Severe Acute Pain

Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Marketing Authorization for Trikafa® for People with Cystic Fibrosis Aged 2 Years and Older with Certain Rare Mutations

Vertex Pharmaceuticals Incorporated to Report Q2, 2024 Results on Aug 01, 2024

Vertex Pharmaceuticals, Inc. Announces Positive Results from Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) completed the acquisition of Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders.

Vertex Pharmaceuticals Incorporated Appoints Jennifer Schneider as Independent Director

Vertex Pharmaceuticals Incorporated Re-Iterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$4.26 (vs US$2.72 in 1Q 2023)

Vertex Pharmaceuticals Announces European Commission Approval for KALYDECO to Treat Infants with Cystic Fibrosis Ages 1 Month and Older

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion.

Vertex Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 06, 2024

Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 15, 2024

Vertex Pharmaceuticals Incorporated Announces New Drug Submission for Exagamglogene Autotemcel (Exa-Cel) Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Receives CHMP Positive Opinion for KALYDECO for the Treatment of Infants with Cystic Fibrosis Ages 1 Month and Older

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Positive Results from Pivotal Trials of Vanza Triple Combination Treatment for Cystic Fibrosis

Vertex Pharmaceuticals Incorporated Provides Product Revenue Guidance for the Full Year 2024

Full year 2023 earnings released: EPS: US$14.05 (vs US$12.97 in FY 2022)

Vertex Announces Positive Results from the VX-548 Phase 3 Program for the Treatment of Moderate-To-Severe Acute Pain

Vertex Pharmaceuticals Incorporated to Report Q4, 2023 Results on Feb 05, 2024

Vertex Pharmaceuticals Incorporated Announces US FDA Approval of CASGEVY™ (Exagamglogene Autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Kingdom of Saudi

Vertex Pharmaceuticals Incorporated Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States

Vertex Pharmaceuticals Incorporated Appoints Nancy Thornberry to Its Board of Directors as an Independent Director

Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older

Vertex Pharmaceuticals Incorporated Announces European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5

Vertex Pharmaceuticals Incorporated Announces United Kingdom Medicines and Healthcare Products Regulatory Agency Granted Conditional Marketing Authorization for CASGEVY

Third quarter 2023 earnings released: EPS: US$4.01 (vs US$3.63 in 3Q 2022)

Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Market Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 To 5 Years With at Least One F508del Mutation

Vertex Pharmaceuticals Incorporated to Report Q3, 2023 Results on Nov 06, 2023

Vertex Pharmaceuticals Incorporated Appoints Michel Lagarde to Its Board of Directors

Vertex Pharmaceuticals Incorporated Receives Chmp Positive Opinion for Kaftrio® (Ivacaftor/Tezacaftor/Elexacaftor) in Combination with Ivacaftor for Children with Cystic Fibrosis Ages 2 Through 5

Vertex Pharmaceuticals Incorporated Appoints E. Morrey Atkinson, Ph.D., as Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations

Vertex Pharmaceuticals Incorporated Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine

Second quarter 2023 earnings released: EPS: US$3.55 (vs US$3.17 in 2Q 2022)

Vertex Pharmaceuticals Incorporated Announces European Commission Approval for ORKAMBI® (Lumacaftor/Ivacaftor) for the Treatment of Children with Cystic Fibrosis Ages 1 to <2 Years Old

Insufficient new directors

Vertex Pharmaceuticals Incorporated Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions

Vertex Pharmaceuticals Incorporated and Crispr Therapeutics Announces Positive Results from Pivotal Trials of Exa-Cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce FDA Accepts Biologics License Applications for Exagamglogene Autotemcel (Exa-Cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

First quarter 2023 earnings released: EPS: US$2.72 (vs US$2.99 in 1Q 2022)

Full year 2022 earnings released: EPS: US$12.97 (vs US$9.09 in FY 2021)

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) announces an Equity Buyback for $3,000 million worth of its shares.

Vertex Pharmaceuticals Incorporated to Report Q4, 2022 Results on Feb 07, 2023

Vertex Pharmaceuticals Incorporated Announces to Present New Data on its Portfolio of Cystic Fibrosis Medicines at 2022 North American Cystic Fibrosis Conference

Third quarter 2022 earnings released: EPS: US$3.63 (vs US$3.30 in 3Q 2021)

Vertex Pharmaceuticals Incorporated Revises Revenue Guidance for the Fiscal 2022

Vertex Pharmaceuticals Incorporated to Report Q3, 2022 Results on Oct 27, 2022

Vertex Pharmaceuticals Incorporated Advances Program Targeting Alpha-1 Antitrypsin Deficiency

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022

Vertex Pharmaceuticals Incorporated Appoints Jonathan Biller as Chief Legal Officer, Effective September 19, 2022

Vertex Pharmaceuticals Incorporated Appoints Jonathan Biller as Chief Legal Officer, Effective September 19, 2022

Vertex Announces U.S. FDA Approval for Orkambi® (Lumacaftor/Ivacaftor) in Children with Cystic Fibrosis Ages 12 to <24 Months

Second quarter 2022 earnings released: EPS: US$3.17 (vs US$0.26 in 2Q 2021)

Vertex Pharmaceuticals Incorporated Reports Unaudited Intangible Asset Impairment Charge for the Three Months Ended June 30, 2022

Vertex Advances VX-548 in Acute and Neuropathic Pain

Vertex Pharmaceuticals Incorporated to Report Q2, 2022 Results on Aug 04, 2022

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into a definitive agreement to acquire ViaCyte, Inc. from Sanderling Ventures, RA Capital Management, L.P., The Invus Group, LLC, Asymmetry Ventures LLC and others for approximately $320 million.

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into a definitive agreement to acquire ViaCyte, Inc. from Sanderling Ventures, RA Capital Management, L.P., The Invus Group, LLC, Asymmetry Ventures LLC and others for approximately $320 million.

Vertex Announces FDA Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes

Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference

Vertex Pharmaceuticals Incorporated Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA